Anti-infectives Developed as Racemic Drugs in the 21st Century: Norm or Exception?
Diego González Cabrera1, Dennis A Smith2, Gregory S Basarab1
1Drug Discovery and Development Centre (H3D), University of Cape Town, Rondebosch 7701, South Africa.
Abstract:
This viewpoint outlines the case for developing new chemical entities (NCEs) as racemates in infectious diseases and where both enantiomers and racemate retain similar on- and off-target activities as well as similar PK profiles. There are not major regulatory impediments for the development of a racemic drug, and minimizing the manufacturing costs becomes a particularly important objective when bringing an anti-infective therapeutic to the marketplace in the endemic settings of infectious diseases.
Related Concept Videos
Racemic Mixtures and the Resolution of Enantiomers
Development of Antibiotic Resistance
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Microorganisms in Medicine and Therapeutics
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
Antimicrobial Effectiveness


